source
- FDA greenlights Revolution Medicines' pancreatic cancer gamechangerFollowing dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approved by the FDA for…Fierce Biotech · 10h ago↗ source
- Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debateFresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…Fierce Biotech · 11h ago↗ source
- FDA expands labels for J&J’s Imaavy and Jazz’s Ziihera; Teva under Turkish antitrust probeThe U.S. Food and Drug Administration has broadened the approved uses for Johnson & Johnson’s oncology drug Imaavy and Jazz Pharmaceuticals’ Ziihera, adding new indications to each label. These la…